Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Aurobindo Pharma Limited — Q2 FY25
Aurobindo Pharma delivered a steady Q2 FY25 with revenue of INR 7,796 crore (+8% YoY) and EBITDA margin of 20.1%, despite higher R&D costs and penicillin G ramp-up losses.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma delivered a steady Q2 FY25 with revenue of INR 7,796 crore (+8% YoY) and EBITDA margin of 20.1%, despite higher R&D costs and penicillin G ramp-up losses. PAT grew 8.6% YoY to INR 817 crore. Growth was driven by strong volume expansion in US oral generics (+9% YoY to $289M) and robust Europe performance (+19% YoY in INR terms). The injectable business faced supply chain headwinds at Unit 3, but management expects normalization by Q4. Penicillin G is on track for breakeven by Q4 FY25. Management reiterated FY25 EBITDA margin guidance of 21%-22%, implying a stronger H2. Key risks include sustained high R&D spend for biosimilar trials and potential freight cost volatility from Red Sea disruptions.
ऑरोबिंदो फार्मा ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 7,796 करोड़ रुपये रही, जो पिछले साल से 8% ज्यादा है। मुनाफा 817 करोड़ रुपये रहा, जो 8.6% बढ़ा है। अमेरिका में जेनेरिक दवाओं की बिक्री 9% और यूरोप में 19% बढ़ी। हालांकि, रिसर्च पर ज्यादा खर्च और पेनिसिलिन जी के उत्पादन में शुरुआती घाटे के बावजूद कंपनी का मुनाफा मार्जिन 20.1% रहा। कंपनी को उम्मीद है कि साल के अंत तक पेनिसिलिन जी घाटे से बाहर आ जाएगी। पूरे साल के लिए मुनाफा मार्जिन 21-22% रहने का अनुमान है। मुख्य चुनौतियां रिसर्च पर ज्यादा खर्च और लाल सागर के रास्ते में माल ढुलाई की लागत में उतार-चढ़ाव हैं।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Sustained high R&D spend
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Oral Generic Revenue
$289M
+9% YoY
Driven by volume gains and new product launches; 14 products launched in Q2.
Europe Formulation Revenue (CC)
EUR 229M
+16% YoY
Strong performance across key geographies; no one-offs according to management.
Global Injectable & Specialty Sales
$121M
-11% YoY (US injectables)
Decline due to supply chain challenges at Unit 3; recovery expected by Q4.
Penicillin G Batches in Q2
35 batches
Ramping to 35-40/month
Commercial batches underway; breakeven targeted by Q4 FY25.
What Changed vs Last Quarter
NEW
Penicillin G breakeven by Q4 FY25
Expect to achieve breakeven at the penicillin G facility by Q4 FY25, with positive contribution from FY26.
NEW
Global Eugia injectable sales ~$600M for FY25
Despite Q1/Q2 slowdown, management expects full-year injectable sales to be around $600M, with a possible 5% variance.
NEW
Biosimilar denosumab commercial in Europe by CY2026
Phase III recruitment completed; filing expected in 2025 with commercialization in Europe in 2026.
UPDATED
FY25 EBITDA margin target of 21%-22%
Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.
DROPPED
Europe revenue to exceed EUR 880 million for FY25
Europe formulations on track to achieve EUR 880 million+ for FY25, with potential to reach EUR 900 million.
DROPPED
Pen-G plant ramp-up from October 2024
Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.
DROPPED
China plant commercialization from Q3 FY25
China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
NEW RISK
Sustained high R&D spend
R&D costs jumped ~INR 70 crore in Q2 due to phase III biosimilar trials; management expects elevated spend for at least four more quarters.
NEW RISK
Freight cost volatility from Red Sea disruptions
Higher freight costs (~INR 30 crore impact) due to Red Sea issues; management expects normalization but uncertainty remains.
NEW RISK
Unit 3 injectable supply chain recovery timeline
Injectable sales declined 11% YoY due to voluntary production slowdown at Unit 3; full recovery expected only by Q4, with FDA reinspection likely in FY26 Q3.
RISK GONE
Pen-G ramp-up delays
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
RISK GONE
Injectables remediation and FDA compliance
Eugia Unit III remediation cost $9M in Q1; Bhiwadi plant received OAI. Further regulatory actions could disrupt injectable sales.
RISK GONE
US price erosion and competition
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q3 FY24
China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Mentioned in Q1 FY24, Q1 FY25
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
Mentioned in Q1 FY25, Q2 FY24
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
Fast read
Guidance and risk preview
Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.
R&D costs jumped ~INR 70 crore in Q2 due to phase III biosimilar trials; management expects elevated spend for at least four more quarters.
View Risks →